Screening of a human breast epithelial cell cDNA library with the tyrosine-phosphorylated C terminus of the epidermal growth factor receptor identified a novel member of the GRB7 gene family, designated GRB14. In addition to a pleckstrin homology domain-containing central region homologous to the Caenorhabditis elegans protein F10E9.6/mig 10 and a C-terminal Src homology 2 (SH2) domain, a conserved N-terminal motif, P(S/A)IPNPFPEL, can now be included as a hallmark of this family. GRB14 mRNA was expressed at high levels in the liver, kidney, pancreas, testis, ovary, heart, and skeletal muscle. Anti-Grb14 antibodies recognized a protein of approximately 58 kDa in a restricted range of human cell lines. Among those of breast cancer origin, GRB14 expression strongly correlated with estrogen receptor positivity, and differential expression was also observed among human prostate cancer cell lines. A GST-Grb14 SH2 domain fusion protein exhibited strong binding to activated platelet-derived growth factor (PDGF) receptors (PDGFRs) in vitro, but association between Grb14 and β-PDGFRs could not be detected in vivo. In serum-starved cells, Grb14 was phosphorylated on serine residues, which increased with PDGF, but not EGF, treatment. Grb14 is therefore a target for a PDGF-regulated serine kinase, an interaction that does not require PDGFR-Grb14 association.

Many intracellular targets for receptor tyrosine kinases (RTKs) contain one or more SH2 domains. These are conserved, noncatalytic domains of approximately 100 amino acids that bind to short peptide sequences containing phosphorylated serine (1). Since receptor autophosphorylation on specific tyrosine residues follows RTK activation, SH2 domains mediate receptor-substrate interactions as well as other protein-protein interactions during signal transduction. Since the specificity of SH2 domain binding is largely determined by amino acid residues C-terminal to the phosphorylserine, the particular autophosphorylation sites present on a given RTK define the SH2 domain-containing signaling proteins that it can recruit and hence, to a large extent, the signaling specificity of the receptor. The CORT technique, in which cDNA expression libraries are screened with the tyrosine-phosphorylated C terminus of the EGF receptor, represents a powerful methodology for the identification and characterization of novel, SH2 domain-containing, receptor substrates (2–5).

SH2 domains are often accompanied in signaling proteins by two other conserved protein modules: SH3 domains, which bind to proline-rich peptide ligands with a PXXP core sequence (6) and thereby also mediate protein-protein interactions, and PH domains. The latter are conserved protein modules now identified in about 60 intracellular proteins, most of which either perform a signaling function or are associated with the membrane cytoskeleton (7). Despite the frequent occurrence of the PH domain and the recent definition of its three-dimensional structure (8–11) the precise role of this module remains obscure. Although several PH domains bind to the βγ subunits of heterotrimeric G proteins (12), this interaction appears to involve only the C-terminal region of the domain. Two other groups have reported protein-protein interactions mediated by PH domains; Yao et al. observed binding of the Btk PH domain to protein kinase C (13), whilst the PH domain of Akt contributes to homotypic oligomerization and kinase regulation (14). However, another possibility is that not all PH domain ligands are protein in nature, since several of these domains bind phosphatidylinositol 4,5-bisphosphate (15), and inositol 1,4,5-trisphosphate represents a high affinity ligand for the phospholipase C-δ1 PH domain (16).

SH2 domain-containing proteins can be divided into two classes (17): class I, which also possesses a catalytic function, e.g. phospholipase C-γ1 and Ras-GAP, and class II, which contain only noncatalytic protein modules and are thought to function as adaptors, linking separate catalytic subunits to receptors or other signaling proteins. A member of the latter class is Grb2, which consists of a SH2 domain flanked by two SH3 domains. The SH2 domain acts as a binding site for specific tyrosine-phosphorylated proteins including the EGF receptor and Shc, while the SH3 domains bind proline-rich sequences in the Ras GDP-GTP exchanger Son of Sevenless (18).

Members of the ErbB family of RTKs and their ligands are implicated both in normal mammary gland development and the growth and progression of human breast cancer (19). Furthermore, marked alterations in the expression or activity of several SH2 domain-containing proteins have been observed in human breast cancers or breast cancer-derived cell lines, suggesting that this represents an additional level at which RTK signaling may be modulated in this disease (20). We therefore chose the human mammary epithelial cell line HMEC184 as a model system on which to base a CORT screening program and
hence identify novel, relatively tissue-specific, ErbB receptor targets.

MATERIALS AND METHODS

cDNA Library Construction—Total cellular RNA was prepared by
the guanidinium isothiocyanate-cesium chloride procedure (21) and
poly(A)\(^+\) RNA isolated using Dynabeads (Dynal, Carlson
South, Victoria, Australia). Double-stranded cDNA was synthesized using the
ZAP-cDNA synthesis kit (Stratagene, La Jolla, CA) with the following
modifications. First strand cDNA synthesis was primed using an oligo-
d(GTTGACCGGTCA) and HindIII primer-adaptor, Novagen, Madison, WI.
Following second strand synthesis, EcoRI adaptors were ligated to the
cDNA, which was then cleaved into HindIII-EcoRI-digested \(\varepsilon\)XElOx (No-
vagen). Two cDNA libraries were constructed. In the first library,
5'-methyl dCTP was incorporated into the first strand cDNA, and the
primary library (approximately \(4 \times 10^8\) recombinants) was amplified on
ER1647 cells prior to screening on strain BL21(DE3)pLysE. A second small library was also made in which the first strand cDNA
was not methylated; this library (approximately \(2 \times 10^8\) recombinants)
was plated directly on BL21(DE3)pLysE cells and screened
unamplified.

Library Screening—Approximately \(1 \times 10^8\) recombinants from the
amplified library and the entire unamplified library were screened by the
\(\varepsilon\)XElOx technique as described previously (5), except that duplicate
plaque lifts were performed. Following the isolation of the initial
GRB14 cDNA, further clones were isolated from either the 184 cDNA
library or a human \(\lambda\)gt11 liver 5' stretch cDNA library (Clontech, Palo
Alto, CA) by standard DNA hybridization techniques (21). DNA probes
were labeled by random primer extension (Promega, Sydney, NSW,
Australia) using [\(\alpha\]\(^32\)P]dTTP (110 TBq/mmol, Amersham Australia Pty
Ltd, Castle Hill, NSW, Australia).

Clone Characterization and DNA Sequencing—Following plaque pu-
fication of \(\varepsilon\)XElOx recombinants, the corresponding \(\varepsilon\)XElOx plasmid was
excised using bacterial strain BM25. DNA mini-preps were then
prepared, and the plasmids were transformed into DH5\(\alpha\) for further analysis. In the case of \(\lambda\)gt11 recombinants, the corresponding EcoRI
inserts were cloned into pBluescript (Stratagene) for sequenc-
ing. DNA sequencing was performed by the dyeodeoxy chain termination
method using Sequenase 2.0 (Bresatec, Adelaide, SA, Australia).

Amino acid sequence alignments were performed using the computer
programs Clustal W and SeqVU.

Northern Blot Analysis—Human multiple tissue Northern blots (Clontech)
were hybridized under conditions recommended by the manu-
facturer. For analysis of GRB14 gene expression in cell lines, total
cellular RNA was isolated, fractionated, and subjected to Northern
analysis as described previously (22). Blots were hybridized with an
882-bp EcoRI fragment from clone 1–1 (Fig. 2A) labeled by random
primer extension (Promega) using [\(\alpha\]\(^32\)P]dTTP (Amersham).
cDNA Expression Vectors—CMV promoters provide vectors for the human
EGFR and the \(\beta\)-PDGFR as were described previously (23).

A Flag epitope-tagged Grb14 eukaryotic expression vector was con-
structed as follows. The complete open reading frame of GRB14 was
first assembled in the vector pRcCMV (Invitrogen Corp., San Diego,
CA) using DNA restriction fragments derived from cDNA clones L5 (in
pBluescript SK+) and 1–2 (in pEExlo) (Fig. 2A). Briefly, L5 was di-
gested with SbaI (which cuts in the vector polylinker) and AvrII to
delate a 93-bp fragment harboring an Apal site from the 5' end of
this cDNA (Fig. 2A). The digested vector was then religated, and a restric-
tion fragment from between the Xbal site in the polylinker and Apal
site in the cDNA prepared and cloned into pRCMV. The GRB14 open
reading frame was then completed by finding a BamHI fragment encoding
the C-terminal region of Grb14 from clone 1–2 into this vector.
However, the resulting expression vector produced only low yields of
recombinant Grb14 in a coupled transcription/translation system (Pro-
mega). Enhanced expression of Grb14 was achieved by deletion of a
GC-rich region S of the translation start codon. This was achieved by
synthesizing the GRB14 open reading frame using polymerase chain
reaction from the GRB14 PCR-cDNA template using oligonucleotide primers containing HindIII (5') and BamHI (3') sites for
directional cloning. This DNA fragment was inserted between the
HindIII and BglII sites of pRCMV\(_{\text{inno}}\), a modified version of pRCMV
designed for tagging of expressed proteins with the \(\beta\)-amino acid Flag
epitope (DYKDDDDK) (24) at the C terminus. The construction of
pRCMV\(_{\text{inno}}\) will be described in detail elsewhere. The sequence of the
GRB14 cDNA in this vector was confirmed by DNA sequencing.

Generation of GST Fusion Proteins—A DNA fragment corresponding
to the SH2 domain of Grb14 (amino acids 426–540) was synthesized by
polymerase chain reaction using Grb14 cDNA as a template and flank-
ing primers containing restriction sites suitable for in-frame insertion
into pGEX2T (Amrad Pharmacia Biotech, Melbourne, Victoria, Au-
stria). A similar strategy was used to clone the mouse Grb7 SH2 domain
(amino acids 418–535) into pGEX2T, except that the cDNA encoding
this region was initially synthesized by reverse tran-
crase chain reaction from mouse liver RNA. Following construction, the
recombinant plasmids were used to transform Escherichia coli DHS\(\alpha\) to
ampicillin resistance. Both constructs were verified by DNA sequenc-
ing. Fusion proteins were purified from isopropyl-\(-\beta\)-thiogalactopy-
rano-side-induced bacterial cultures as described previously (25).

Clonal Culture—HMEC 1B18 was obtained from Dr. Martha Stampfer (University of California, Berkeley). HMEC 1001–7 and HMEC 219–4 cells were obtained from Clonetics Corp. (San Diego, CA). All HMEC lines were maintained in
memmorial epithelial growth medium (Clonetics). Maintenance of hu-
mn breast cancer cell lines was as described previously (26). The
human prostate cancer cell lines DU145, LnCap, and PC3 were ob-
tained from the ATCC (Rockville, MD), while the human epidermoid carcinoma cell line A431 was obtained from the Ludwig Institute for
Cancer Research (Melbourne, Australia). These cell lines were main-
tained in the same medium as the breast cancer cell lines. HEK 293 cells were obtained from the ATCC and maintained in modified Eagle’s
medium (CSL Biosciences, Parkville, Victoria, Australia) supplemented
with 100 units/ml penicillin, 2 mM glutamine, 6.7 mM sodium
bicarbonate, and 10% FCS (CSL Biosciences). Cells were starved in
medium containing 0.5% FCS prior to preparation of cell
lysates for protein analysis. HER14 and HER1–2 cells were transfected
with NIH3T3 fibroblasts expressing the human EGFR and EGFR/Erbb2
chimeras, respectively, were maintained as described previously (27,28).

Prior to growth factor treatment the cells were starved overnight in
Dulbecco’s modified Eagle’s medium (CSL Biosciences) containing 0.5%
calf serum (CSL Biosciences).

Commercial antibodies were used as follows: monoclonal anti-phosphotyrosine antibody PY20 (Transduction Labora-
tories, Lexington, KY); anti-EGFR monoclonal antibody clone 22S
(27,28). The TR-FRET methodology provided the additional advantage of removing anti-GST
antibodies in the same step. Briefly, the pExlox plasmid containing
GRB14 clone 1 (Fig. 2A) was excised and transformed into E. coli BL21
DE3 pLysE. Lysates from isopropyl-\(-\beta\)-thiogalactopyranoside-induced
bacteria were separated by SDS-PAGE and transferred to nitrocel-
llose, and the position of the induced fusion protein was identified by
Ponceau S staining. The filters were then incubated with crude anti-
serum diluted 1:1 in Tris-buffered saline, and following washing, the
anti-Grb14 antibodies were eluted from the appropriate region of the
filter on a TURBO 3 gel (Amersham). The blots were
neutralized with 0.2 \(\times\) volume of 1 \(\times\) Tris-HCl, pH 8.0, concentrated,
and finally subjected to buffer exchange with Tris-buffered saline (10
\(\mu\)l Tris-HCl, 150 \(\mu\)l NaCl, pH 7.4) using a Centricon 30 microcon-
centrator (Amicon, Beverly, MA). The affinity-purified antibody was then
quantitated, adjusted to 0.1% bovine serum albumin, and stored at
70°C.

Cell Lysis, Immunoprecipitation, and Western Blotting—These tech-
niques were as described previously (30), except that a modified radio-
immunoprecipitation buffer was used to wash immunoprecipitates from
metabolically radiolabeled cells (3).

Densitometric analysis of autoradiographs was performed using the
IP Lab Gel analysis program (Signal Analytics Corp., Vienna, Virginia).

Binding Assays—Following cell lysis, 300 \(\mu\)l of lysate was incubated with
5 \(\mu\)g of GST fusion protein coupled to glutathione-agarose beads for
2 h at 4°C. The beads were then washed 3 \(\times\) with cell lysis buffer
Cloning of GRB14, a Novel GRB7 Family Member

**RESULTS**

Screening of a Normal Breast Epithelial Cell cDNA Library by the CORT Technique—CORT screening of the two cDNA libraries prepared from strain 184 normal breast epithelial cells led to the isolation of several recombinants that exhibited differential binding to the phosphorylated EGFR C terminus; the results for some of these clones are shown in Fig. 1. Upon excision of the corresponding pEXlox plasmids and sequencing of the DNA inserts, two recombinants that bound very strongly were identified as GRB2 cDNA clones (3), and a clone exhibiting moderate binding and designated GRB13 according to CORT nomenclature corresponded to Ras-GAP (33). The final clone shown in the figure, GRB14, bound only weakly to the EGFR.

A data base search with the corresponding cDNA sequence did not detect an exact match but revealed significant sequence homology with the SH2 domain-containing protein Grb7 (2). The cDNA (GRB14 clone 1 in Fig. 2A) encoded a short stretch of amino acids followed by a C-terminal SH2 domain; homology to GRB7 was apparent over this entire open reading frame.

Characterization of GRB14—In order to obtain the full-length cDNA sequence for GRB14, two cDNA library screens were performed. In the first, the cDNA insert from clone 1 was used to screen the strain 184 cDNA library. Screening of $5 \times 10^5$ recombinants isolated 2 cDNAs, designated 1-1 and 1-2, of 1.6 and 1.4 kb, respectively (Fig. 2A). In the second, a 213-bp EcoRI-Xhol restriction fragment derived from 1-1 (Fig. 2A) was used to screen a human liver cDNA library. Abbreviations are as follows: Av, AvrII, X, XhoI, E, EcoRI. The numbers refer to distances in bp. Nucleotide and amino acid sequence alignment below. The initial clone isolated by CORT screening was designated clone 1. Two other clones (1-1 and 1-2) were isolated from the 184 cell line library by screening using clone 1 as a probe. The GRB14 cDNA sequence was completed using two clones, L5 and L6, isolated from a human liver cDNA library. Abbreviations are as follows: Av, AvrII, X, XhoI, E, EcoRI. The numbers refer to distances in bp.
sequence derived from these overlapping clones corresponds closely to the size of the most abundant mRNA species detected upon Northern blot analysis (Fig. 4).

Analysis of the cDNA sequence identified an open reading frame of 540 amino acids. The initiation codon is preceded by an in-frame termination codon and is surrounded by a consensus sequence for strong translational initiation (34). The encoded protein is similar both in molecular architecture and amino acid sequence to Grb7 (2) and the recently identified Grb10 (4), consisting of an N-terminal region containing at least one proline-rich motif, a central region of approximately 320 amino acids, which exhibits significant homology to the C. elegans protein F10E9.6/mig 10 (4, 35) and which also encompasses a PH domain, and a C-terminal SH2 domain. An alignment of the amino acid sequences of Grb14, Grb7, Grb10 and F10E9.6 is shown in Fig. 3.

Grb14 is similar in size to Grb7, Grb10 possessing a more extended N terminus. The N-terminal regions of Grb14, Grb7, and Grb10 exhibit low sequence homology apart from a highly conserved amino acid motif P(S/A)IPNPFPEL. Also of note is the presence of two clusters of basic residues, which flank this motif. Overall, the N-terminal region of Grb14 displays a lower proline content than that of Grb7 and Grb10 (Grb14 amino acids 1–110, 11% proline; Grb10 amino acids 1–113, 15%; Grb7 amino acids 1–103, 23%).

In the conserved central region, Grb14 bears 48, 55, and 28% amino acid identity, respectively, with Grb7, Grb10, and F10E9.6 (Fig. 3). The core of this region is provided by a PH domain.
domain (Figs. 2 and 3) (7), over which Grb14 exhibits 56, 61, and 35% amino acid identity, respectively, with Grb7, Grb10, and F10E9.6. However, as noted by Ooi et al. (4), another region of marked homology spanning approximately 100 amino acids exists amino-terminal to the PH domain (Fig. 3). The most highly conserved region among Grb7 family members is the SH2 domain (Fig. 3). The Grb14 SH2 domain displays 67 and 74% amino acid identity, respectively, with the corresponding domain in Grb7 and Grb10.

Northern Blot Analysis of Grb14 Gene Expression—The tissue specificity of Grb14 gene expression was investigated by hybridizing Northern blots of poly(A)⁺ RNA isolated from a variety of human tissues to a GRB14-specific cDNA probe. GRB14 gene expression was highest in the testis, ovary, heart, liver, skeletal muscle, kidney, and pancreas. Moderate expression was detected in the small intestine, colon, peripheral blood leukocytes, brain, and placenta, while expression in the spleen, thymus, prostate, and lung was low or undetectable. Several mRNA transcripts were detected that displayed tissue-specific variation in their relative abundance. The three most prominent transcripts were approximately 2.3, 2.4, and 2.5 kb. Often co-expressed with one or two of these transcripts was a transcript of approximately 9.5 kb. In the ovary a still larger transcript of undetermined size was also expressed.

Since the GRB14 cDNA was originally isolated from a cDNA library prepared from normal human breast epithelial cells, we were interested in determining the expression profile of GRB14 mRNA in a panel of human breast cancer cell lines. Upon Northern blot analysis of total RNA isolated from 3 normal human breast epithelial cell strains and 19 human breast cancer cell lines, GRB14 gene expression could be detected in HMEC 184 and HMEC-219-4 cells, 6/7 ER+ human breast cancer cell lines, and 2/12 ER− cell lines (Table I). Thus GRB14 gene expression appears largely restricted to normal breast epithelial and ER+ breast cancer cells. Differential expression of GRB14 was also observed among human prostate cancer cell lines. Although GRB14 mRNA expression was undetectable in the normal prostate (Fig. 4), low expression could be detected in the PC3 and LnCaP prostate cancer cell lines and high expression in the DU145 line (Table I).

Expression of Grb14 Protein—In order to characterize the Grb14 protein a polyclonal antiserum was raised against a GST-Grb14 SH2 domain fusion protein. Following affinity purification, this antiserum was used to Western blot cell lysates derived from cell lines in which GRB14 mRNA was either expressed at high levels (DU145 and HEK 293) or was undetectable (A431 and SK-BR-3) (Table I). This antiserum recognized a protein of approximately 58 kDa in DU145 cells, while in HEK 293 cells a tight doublet of this mobility was detected (Fig. 5A). These bands were not observed upon Western blotting with preimmune serum or in the cell lines that do not express GRB14 mRNA. This estimated size of Grb14 upon SDS-PAGE is in accordance with the predicted size of the translation product of the GRB14 cDNA (60 kDa). Although Grb14 is of similar size to Grb7, the Grb14 antiserum does not significantly cross-react with this protein, which is expressed at high levels in SK-BR-3 cells (35).

Since DU145 cells overexpress GRB14 mRNA relative to the two other prostate carcinoma cell lines examined (Table I), we investigated whether this was accompanied by an up-regulation of Grb14 protein expression. Upon Western blot analysis, Grb14 was clearly detectable in DU145, but not PC3 or LnCaP, cell lysates (Fig. 5B), indicating that Grb14 protein is overexpressed in this cell line.

Interaction of Grb14 with Activated Growth Factor Receptors—It appears likely that the Grb7 family function as adaptors, binding activated receptors or other tyrosine-phosphorylated proteins via their SH2 domains and recruiting effector proteins via other interaction domains. It was therefore of interest to determine the specificity of Grb14 SH2 domain binding and to compare it with the SH2 domain of another family member, Grb7.

When compared with either the Grb7 (Fig. 6) or the Grb2⁵ SH2 domains for binding to the EGFR, the Grb14 SH2 domain exhibited a relatively weak interaction, as might be predicted from the CORT screening results (Fig. 1). In accordance with other RTK-SH2 domain interactions, the binding of the Grb14 SH2 domain was dependent on ligand stimulation and tyrosine phosphorylation of the receptor. A difference in binding selec-
interaction between the Grb7 and Grb14 SH2 domains was more evident when binding to the activated HER 1–2 receptor (an EGFR/ErbB2 chimera containing the intracellular domain of ErbB2) was investigated. In this experiment the Grb7 SH2 domain bound avidly to the chimeric receptor, as reported by Stein et al. (35), while binding of the Grb14 SH2 domain could not be detected (Fig. 6). However, both the Grb7 and Grb14 SH2 domains exhibited strong binding to activated PDGFRs (Fig. 6), which was more pronounced than that observed with the Grb2 SH2 domain. In Far Western blotting experiments in which specific PDGFRs were immunoprecipitated, separated by SDS-PAGE, transferred to nitrocellulose, and then incubated with soluble GST-Grb14 SH2 domain, direct binding was observed to both activated α- and β-PDGFRs.2

The interaction between Grb14 and RTKs in vivo was studied using two systems: DU145 cells, which express high levels of endogenous Grb14 and 1.5 × 10⁵ EGFRs/cell (36) and transient transfection of HEK 293 cells.2 Western blotting of EGFR immunoprecipitates from EGF-stimulated DU145 cells with anti-Grb14 antiserum did not detect association between these two proteins. Furthermore, upon transient co-expression of the EGFR and Flag epitope-tagged Grb14 in HEK 293 cells, the EGFR could not be detected in Grb14 immunoprecipitates from EGF-stimulated cells. Similarly, following co-transfection of the β-PDGFR and Grb14 cDNAs into HEK 293 cells, Grb14 could not be detected in anti-β-PDGFR immunoprecipitates from PDGF BB-stimulated cells, and vice versa. Therefore, true in vivo binding partners for the Grb14 SH2 domain remain to be identified.

Phosphorylation of Grb14—In order to characterize further the role of Grb14 in RTK signaling, the phosphorylation state of Grb14 was investigated before and after growth factor stimulation. Since the anti-Grb14 antiserum 264 did not immunoprecipitate Grb14 under either native or denaturing conditions, we utilized an expression construct (pRcCMVFlag), which tagged Grb14 with the 8-amino acid Flag epitope at the C terminus. This construct was stably transfected into HEK 293 cells, leading to the isolation of stable clones of cells expressing an epitope-tagged Grb14, which could be immunoprecipitated with the M2 anti-Flag monoclonal antibody and Western blotted with either this antibody or anti-Grb14 antiserum 264 (Fig. 7, A and B). Immunoprecipitation of Grb14 from serum-starved cells that were metabolically labeled with 32P-orthophosphate demonstrated that Grb14 was phosphorylated in this basal state (Fig. 7C). Phosphoamino acid analysis of the isolated protein demonstrated that phosphorylation was on serine residues (Fig. 7D; more prolonged exposures obtained using a Phosphorimager also only detected serine phosphorylation).

Treatment of the cells with EGF did not significantly increase this level of phosphorylation (Fig. 8A), although activation of native EGFRs could be demonstrated by anti-phosphotyrosine blotting of the cell lysates.2 However, stimulation with PDGF BB resulted in an approximately 1.5-fold increase within 5 min of administration, and transient transfection of a cDNA encoding β-PDGFRs into the cells further amplified this response to approximately 2-fold (Fig. 8B). The small increase in phosphorylation that occurred when this construct was present in the absence of PDGF BB was presumably due to the constitutive activation of RTKs often observed with this system (23). Phosphoamino acid analysis demonstrated that the PDGF-induced increases in Grb14 phosphorylation also occurred on serine residues.2

**DISCUSSION**

This paper describes the expression cloning of a novel member of a family of SH2 domain-containing signaling proteins which contains two other proteins cloned by the CORT screening technique, Grb7 (2) and Grb10 (4). The cloning of GRB14...
Cloning of GRB14, a Novel GRB7 Family Member

Fig. 7. Characterization of Flag epitope-tagged Grb14 expressed in HEK 293 cells. A, detection of epitope-tagged Grb14 by Western blot analysis. Lysates were prepared from control untransfected (HEK) and GRB14/pRcCMV transfected (HEK/Grb14) HEK 293 cells. Equivalent amounts of protein were then separated by SDS-PAGE (10% gel), transferred to nitrocellulose, and Western blotted with anti-Flag monoclonal antibody M2. Detection of bound antibody was by ECL. B, Immunoprecipitation of epitope-tagged Grb14. Lysates were prepared from control and transfected HEK 293 cells. Equivalent amounts of protein were then immunoprecipitated (IP) with anti-Flag antibody M2 and subjected to SDS-PAGE (10% gel). Following transfer to nitrocellulose the immunoprecipitates were Western blotted with affinity-purified anti-Grb14 antisem 264 and anti-Flag antibody M2. C, detection of Grb14 phosphorylation. Control and transfected HEK 293 cells were serum-starved and then metabolically labeled with 32P-orthophosphate. Following immunoprecipitation with anti-Flag antibody M2 and SDS-PAGE, the immunoprecipitates were transferred to a PVDF membrane and subjected to autoradiography. The exposure time was 16 h at –70°C with two intensifying screens. D, detection of Grb14 serine phosphorylation. Following detection of PVDF-immobilized phosphorylated Grb14 the band was excised and subjected to phosphoamino acid analysis as described under "Materials and Methods." The mobilities of the phosphoamino acid standards phosphotyrosine (Tyr), phosphothreonine (Thr), and phosphoserine (Ser) were as indicated. The exposure time was 14 days at –70°C with two intensifying screens. An equivalent of a more prolonged exposure achieved using a PhosphorImager also only detected serine phosphorylation.

provides further evidence for the strength of the CORT screening strategy in the identification of novel EGFR binding proteins. In addition to the three members of the GRB7 gene family characterized so far, utilization of this technique also led to the cloning of GRB1/p85 (5) and GRB2 (3). Other SH2 domain-containing proteins isolated using this procedure include phospholipase Cγ (1), Fyn, Nck-like and Crk-like proteins (2), Syp (37), and Ras-GAP (this manuscript). Furthermore, a novel, non-SH2 Tyr(P) interaction (PI) domain in Shc was also initially identified by this technique (38). Interestingly, CORT screening of the 184 cell line cDNA library also led to the isolation of four cDNAs corresponding to a protein lacking clearly recognizable SH2 or PI motifs.

The Grb7 family belong to the adapter subclass of SH2 domain-containing proteins and contain at least three "interactive" protein domains likely to participate in this function. First, the cloning of GRB14 has highlighted an N-terminal proline-rich motif PS(A)IPNPFPPEL, which is completely conserved in all three family members (Fig. 3). This is particularly striking when considered in the context of the poor sequence conservation elsewhere in the N termini of these proteins. The motif conforms to the consensus PXXP SH3 domain binding motif described by Yu et al. (6), suggesting that recruitment of proteins containing a particular subclass of SH3 domain is fundamental to Grb7 family signaling. Interestingly, Grb7 and Grb10 also contain other proline-rich regions harboring PXXP motifs that may provide additional SH3 domain binding sites; however, these are not conserved between the two proteins.

The second region probably involved in intermolecular interaction is the central region of approximately 320 amino acids bearing homology to the C. elegans protein F10E9.6. A key feature of this region is a PH domain, which may mediate protein-protein or protein-phospholipid interactions (7, 15, 39) and hence regulate signaling events and/or subcellular localization. However, since homology with F10E9.6 extends outside the PH domain (in particular to the 100-amino acid region amino-terminal to this domain) it seems likely that other sections of the central region also participate in a conserved signaling function. The only due to the role of this region comes from the recent identification of F10E9.6 as the product of the mig10 gene in C. elegans (4, 35), which is required for longitudinal neuronal migration in embryos (40). However, Grb7 family members and F10E9.6/mig 10 do not exhibit overall structural similarity, the latter containing an unrelated N-terminal region and a proline-rich C terminus flanking the central domain. It therefore remains possible that this central domain represents a protein module found in functionally distinct proteins and that the Grb7 family and F10E9.6/mig 10 perform unrelated signaling roles.

The third interactive domain identified in Grb14 is the SH2 domain. When expressed as a GST fusion protein and utilized for in vitro binding experiments, this domain exhibited a high affinity for a subclass of tyrosine-phosphorylated growth factor receptors, binding strongly to activated PDGF receptors in HER14 cells but only weakly to activated EGF receptors (Fig. 6). Interaction with an EGF-R-ErbB2 chimera was undetectable. This represents a marked difference in binding specificity to the Grb7 SH2 domain, which binds strongly in vitro to the EGF and ErbB receptors (35, 38). The Grb10 SH2 domain, which is more closely related to the Grb14 SH2 domain than that of Grb7, also displays a relatively weak interaction with the EGFR (4). This gene family therefore represents an interesting model system in which to study determinants of SH2 domain binding selectivity. Indeed, we have recently identified...
two amino acid residues in Grb14 that, when changed to their in vivo counterparts, confer high affinity to Grb7 family members or reflect the different cell types utilized in these experiments. This finding suggests that signaling via phorbol ester-activated protein kinase C isoforms is also not the major mechanism for PDGF-induced Grb14 phosphorylation. Determination of the sites of phosphorylation of Grb14 and their degree of conservation among the Grb7 family will provide information into the role of phosphorylation in regulation of the function of these proteins. Also, further characterization of the serine kinase involved and its interaction with Grb14 will also help determine whether this activity represents an integral component of the Grb14 signaling complex.

The Grb7 family members exhibit relatively tissue-specific patterns of expression. GRB14 probably represents the most widely expressed family member and GRB7 the least, expression of the latter gene being restricted to kidney, liver, and gonads (2). These proteins therefore differ from other “adapter” SH2 domain-containing proteins such as Grb2 (3) and Nck (44), which are ubiquitous in their expression. This suggests that the Grb7 family performs a relatively specialized signaling role, with the individual members functioning in a tissue-restricted manner to link specific receptors to effector molecules. This hypothesis is supported by the differences in SH2 domain specificity exhibited by the different family members. However, Grb7 family proteins also exhibit a provocative expression profile among different types of human cancer cells. For example, due to the close proximity of their respective genes and hence coordinate gene amplification, Grb7 is over-expressed along with its binding partner ErbB2 in a subset of human breast cancers (35). Furthermore, our results demonstrate a correlation between GRB14 expression and estrogen receptor positivity in human breast cancer cells and, in a preliminary investigation of human prostate cancer cell lines, marked overexpression in DU145 cells versus the normal prostate and the other prostate cancer lines examined (Table I and Fig. 5). These and other data demonstrating aberrant expression of signaling proteins in human cancer cells (20) identify novel mechanisms for modulation of RTK signaling during tumorigenesis and highlight a potential role for such proteins as tumor markers and/or prognostic indicators.

Acknowledgments—We thank Dr. J. Schlessinger for the provision of the baculovirus-expressed EGF intracellular domain, Grb2 fusion proteins, and HER14 and HER1-2 cell lines; Dr. Xin Wang and Dr. Phil Robinson for assistance with the phosphoamino acid analysis; Helen Ball for the mouse liver RNA; the Neurobiology Division, Garvan Institute, for the human liver cDNA library; Jenny Hamilton and James Gardiner for assistance with computing; and Dr. Ben Margolis for the communication of results prior to publication.

REFERENCES

1. Pawson, T. (1995) Nature 373, 573–580
2. Margolis, B., Silvennoinen, O., Comoglio, F., Roopraptun, C., Skondnik, E., Ullrich, A., and Schlessinger, J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8889–8893
3. Lowenstein, E. J., Daly, R. J., Batzer, A. G., Li, W., Margolis, B., Lamers, R., Ullrich, A., Skondnik, E., Bar-Sagi, D., and Schlessinger, J. (1992) Cell 70, 431–442
4. Ooz, J., Yajnik, V., Immanuel, D., Gordon, M., Mokosk, J. W., Burchberg, A. M., and Margolis, B. (1995) Oncogene 10, 1621–1630
5. Skondnik, E. Y., Margolis, B., Mahamad, M., Lowenstein, E., Fischer, R., Dreppa, A., Ullrich, A., and Schlessinger, J. (1991) Cell 65, 83–90
6. Yu H., Chen, J. K., Feng, S., Dalgarno, D. C., Brauer, A. W., and Schreiber, S. L. (1994) Cell 76, 933–945
7. Gibbons, T. P., Miyasato, K., Musacchio, A., and Saraste, M. (1994) Trends Biochem. Sci. 19, 349–353
8. Downing, A. K., Driscoll, P. C., Gout, I., Salim, K., Zvelebil, M. J., and Waterfield, M. D. (1994) Current Biol. 4, 884–891
9. Ferguson, K. M., Lemmon, M. A., Schlessinger, J., and Sigler, P. B. (1994) Cell 79, 199–209
10. Macias, M. J., Musacchio, A., Porsting, H., Nilges, M., Saraste, M., and Oschkinat, H. (1994) Nature 369, 675–677
11. Yoon, H. S., Hajdok, P. J., Peters, A. M., Oleniczak, E. T., Meadows, R. P., and Fesik, S. W. (1994) Nature 369, 672–675
12. Tounaha, K., Inglese, J., Pitcher, J., Shaw, G., and Lefkowitz, R. J. (1994) J. Biol. Chem. 269, 10217–10220
Cloning of GRB14, a Novel GRB7 Family Member

12510

13. Yao, L., Kawakami, Y., and Kawakami, T. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9175-9179
14. Datta, K., Franke, T. F., Chan, T. O., Makris, A., Yang, S.-I., Kaplan, D. R., Morrison, D. K., Golemis, E. A., and Tsichlis, P. N. (1995) Mol. Cell. Biol. 15, 2304-2310
15. Harlan, J. E., Hajduk, P. J., Yoon, H. S., and Fesik, S. W. (1994) Nature 371, 168-170
16. Lemmon, M. A., Ferguson, K. M., O'Brien, R., Sigler, P. B., and Schlessinger, J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10472-10476
17. Schlessinger, J., and Ullrich, A. (1992) Neuron 9, 383-391
18. Pawson, T., and Gish, G. D. (1992) Cell 71, 359-362
19. Dickson, R. B., and Lippman, M. E. (1988) in Breast Cancer: Cellular and Molecular Biology (Lippman, M. E., and Dickson, R. B., eds) pp. 119-165, Kluwer Academic, Boston
20. Daly, R. J. (1995) Breast Cancer Res. Treat. 34, 85-92
21. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
22. Alexander, I. E., Clarke, C. L., Shine, J., and Sutherland, R. L. (1989) Mol. Endocrinol. 3, 1377-1386
23. Lammers, R., Bossemmaier, B., Cool, D. E., Tonks, N. K., Schlessinger, J., Fischer, E. H., and Ullrich, A. (1993) J. Biol. Chem. 268, 22456-22462
24. Hopp, T. P., Prickett, K. S., Price, V. L., Libby, R. T., March, C. J., Cerretti, D. P., Urdal, D. L., and Conlon, P. J. (1988) Bio/Technology 6, 1204-1210
25. Smith, D. B., and D'Amico, P. (1988) Gene (Amst.) 67, 31-40
26. Buckley, M. F., Sweeney, K. J. E., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., deFazio, A., Watts, C. K. W., Musgrove, E. A., and Sutherland, R. L. (1995) Oncogene 8, 2127-2133
27. Honegger, A. M., Dull, T. J., Felder, S., Van Obberghen, E., Bellot, F., Zapary, D., Schmidt, A., Ullrich, A., and Schlessinger, J. (1987) Cell 51, 199-209
28. Lee, J., Dull, T. J., Lax, I., Schlessinger, J., and Ullrich, A. (1989) EMBO J. 8, 167-173
29. Smith, D. E., and Fisher, P. A. (1984) J. Cell Biol. 99, 20-28
30. Janes, P. W., Daly, R. J., deFazio, A., and Sutherland, R. L. (1994) Oncogene 9, 3601-3608
31. Chen, C., and Okayama, H. (1987) Mol. Cell. Biol. 7, 2745-2752
32. Kamps, M. P. (1993) Methods Enzymol. 201, 21-27
33. Trahey, M. G., Wong, R., Halenback, B., Rubinfeld, G., Martin, M., Ladner, C. M., Long, W. J., Crosset, K., Katt, K., Roth, K., and McCormick, F. (1988) Science 242, 1696-1700
34. Kozak, M. (1989) J. Cell Biol. 108, 229-241
35. Stein, D., Wu, J., Fuqua, S. A. W., Roonprapunt, C., Yajnik, V., D'Eustachio, P., Moskow, J. J., Buchberg, A. M., Osborne, C. K., and Margolis, B. (1994) EMBO J. 13, 1331-1340
36. Connolly, J. M., and Rose, D. P. (1989) Prostate 15, 177-186
37. Lee, C. H., Koninus, D. Jacques, S., Margolis, B., Schlessinger, J., Shoelson, S. E., and Kuriyan, J. (1994) Structure 2, 423-438
38. Blaikie, P., Immelien, D., Wu, J., Li, N., Yajnik, V., and Margolis, B. (1994) J. Biol. Chem. 269, 32031-32034
39. Ferguson, K. M., Lemmon, M. A., Schlessinger, J., and Sigler, P. B. (1995) Cell 83, 1037-1046
40. Manser, J., and Wood, W. B. (1990) Dev. Genet. 11, 49-64
41. Liu, F., and Roth, R. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10287-10291
42. Pandey, A., Duan, H., Di Fiore, P. P., and Dixit, V. M. (1995) J. Biol. Chem. 270, 21461-21463
43. Nishizuka, Y. (1995) FASEB J. 9, 484-496
44. Li, W., Hu, P., Skoldnik, E. Y., Ullrich, A., and Schlessinger, J. (1992) Mol. Cell. Biol. 12, 5824-5833